You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲頂新耀-B(01952.HK)公佈中期業績,研發開支達2.89億元

格隆匯8月24日丨雲頂新耀-B(01952.HK)發佈公吿,截至2023年6月30日止六個月,收益由上年同期的人民幣100萬元增加人民幣790萬元至人民幣890萬元,主要由於在新加坡銷售依嘉®及在與吉利德科學公司(“吉利德”)的過渡期內銷售Trodelvy®所致。 研發開支由上年同期的人民幣3.455億元減少人民幣5700萬元至人民幣2.885億元,主要由於(i)多款候選藥物已完成臨牀試驗並進入註冊階段或商業化階段;及(ii)將 Trodelvy®的臨牀開發活動轉至吉利德。 分銷及銷售開支由上年同期的人民幣1.482億元減少人民幣8410萬元至人民幣6410萬元,主要由於將Trodelvy®的相關商業化活動轉至吉利德以及2022年8月起的相關組織架構優化及合理化所致。

期內虧損淨額由上年同期的人民幣6.68億元減少人民幣2.444億元至人民幣4.236億元,主要由於(i)多款候選藥物已完成臨牀試驗並進入註冊階段或商業化階段;(ii)將Trodelvy®的相關臨牀及商業化活動轉至吉利德;及(iii)組織架構優化和合理化。期內經調整虧損由上年同期的人民幣5.237億元減少人民幣1.968億元至人民幣3.269億元,主要由於國際財務報吿準則虧損縮減所致。截至2023年6月30日,現金及現金等價物以及定期存款為人民幣25.402億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account